PMID- 37894286
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231030
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 20
DP  - 2023 Oct 10
TI  - Pancreatic Neuroendocrine Tumors in MEN1 Patients: Difference in Post-Operative 
      Complications and Tumor Progression between Major and Minimal Pancreatic 
      Surgeries.
LID - 10.3390/cancers15204919 [doi]
LID - 4919
AB  - Pancreatic neuroendocrine neoplasms (PNENs) affect over 80% of patients with 
      multiple endocrine neoplasia type 1 (MEN1). Surgery is usually the therapy of 
      choice, but the real immediate and long-term therapeutic benefit of a partial 
      extensive pancreatic resection remains controversial. We analyzed, in 43 PNEN 
      MEN1 patients who underwent 19 pancreaticoduodenectomies (PD), 19 distal 
      pancreatectomies (DP), and 5 minimal pancreatectomies, the prevalence of 
      surgery-derived early complications and post-operative pancreatic sequelae, and 
      the PNEN relapse-free survival time after surgery, comparing major (PD+DP) and 
      minimal pancreatic surgeries. No post-operative mortality was observed. 
      Metastatic cancers were found in 12 cases, prevalently from duodenal gastrinoma. 
      Long-term cure of endocrine syndromes, by the 38 major pancreatic resections, was 
      obtained in 78.9% of gastrinomas and 92.9% of insulinomas. In only one patient, 
      hepatic metastases, due to gastrinoma, progressed to death. Out of the 38 major 
      surgeries, only one patient was reoperated for the growth of a new PNEN in the 
      remnant pancreas. No functioning PNEN persistence was reported in the five 
      minimal pancreatic surgeries, PNEN relapse occurred in 60% of patients, and 40% 
      of cases needed further pancreatic resection for tumor recurrence. No significant 
      difference in PNEN relapse-free survival time after surgery was found between 
      major and minimal pancreatic surgeries.
FAU - Tonelli, Francesco
AU  - Tonelli F
AD  - Fondazione F.I.R.M.O. Onlus, Fondazione Italiana per la Ricerca sulle Malattie 
      dell'Osso (Italian Foundation for the Research on Bone Diseases), 50129 Florence, 
      Italy.
AD  - Donatello Bone Clinic, Villa Donatello Hospital, 50019 Sesto Fiorentino, Italy.
FAU - Marini, Francesca
AU  - Marini F
AUID- ORCID: 0000-0002-3678-4922
AD  - Fondazione F.I.R.M.O. Onlus, Fondazione Italiana per la Ricerca sulle Malattie 
      dell'Osso (Italian Foundation for the Research on Bone Diseases), 50129 Florence, 
      Italy.
FAU - Giusti, Francesca
AU  - Giusti F
AUID- ORCID: 0000-0002-8576-9606
AD  - Donatello Bone Clinic, Villa Donatello Hospital, 50019 Sesto Fiorentino, Italy.
AD  - Department of Experimental and Clinical Biomedical Sciences, University of 
      Florence, 50139 Florence, Italy.
FAU - Iantomasi, Teresa
AU  - Iantomasi T
AUID- ORCID: 0000-0001-7461-330X
AD  - Department of Experimental and Clinical Biomedical Sciences, University of 
      Florence, 50139 Florence, Italy.
FAU - Giudici, Francesco
AU  - Giudici F
AUID- ORCID: 0000-0002-6879-5685
AD  - Department of Clinical and Experimental Medicine, Surgical Unit, University of 
      Florence, 50139 Florence, Italy.
FAU - Brandi, Maria Luisa
AU  - Brandi ML
AUID- ORCID: 0000-0002-8741-0592
AD  - Fondazione F.I.R.M.O. Onlus, Fondazione Italiana per la Ricerca sulle Malattie 
      dell'Osso (Italian Foundation for the Research on Bone Diseases), 50129 Florence, 
      Italy.
AD  - Donatello Bone Clinic, Villa Donatello Hospital, 50019 Sesto Fiorentino, Italy.
LA  - eng
PT  - Journal Article
DEP - 20231010
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10605506
OTO - NOTNLM
OT  - distal pancreatectomy (DP)
OT  - minimal pancreatic surgeries
OT  - multiple endocrine neoplasia type 1 (MEN1)
OT  - pancreatic neuroendocrine neoplasms (PNENs)
OT  - pancreaticoduodenectomy (PD)
COIS- All the authors declare they do not have any conflict of interest related to this 
      study.
EDAT- 2023/10/28 11:44
MHDA- 2023/10/28 11:45
PMCR- 2023/10/10
CRDT- 2023/10/28 01:14
PHST- 2023/09/05 00:00 [received]
PHST- 2023/09/29 00:00 [revised]
PHST- 2023/10/05 00:00 [accepted]
PHST- 2023/10/28 11:45 [medline]
PHST- 2023/10/28 11:44 [pubmed]
PHST- 2023/10/28 01:14 [entrez]
PHST- 2023/10/10 00:00 [pmc-release]
AID - cancers15204919 [pii]
AID - cancers-15-04919 [pii]
AID - 10.3390/cancers15204919 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Oct 10;15(20):4919. doi: 10.3390/cancers15204919.